NKTR - Nektar Therapeutics

NasdaqGS - NasdaqGS Real-time price. Currency in USD
48.73
-0.35 (-0.71%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close49.08
Open0.00
Bid45.00 x 100
Ask53.59 x 100
Day's range47.99 - 49.19
52-week range17.51 - 111.36
Volume1,552,385
Avg. volume4,324,628
Market cap8.352B
Beta2.85
PE ratio (TTM)N/A
EPS (TTM)-0.81
Earnings date6 Aug 2018 - 10 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est96.78
Trade prices are not sourced from all markets
  • Puma Biotechnology Enters into Collaboration with Strata Oncology
    Market Realist5 days ago

    Puma Biotechnology Enters into Collaboration with Strata Oncology

    Puma Biotechnology Enters into Collaboration with Strata OncologyPuma’s collaboration with Strata Oncology

  • Why Advaxis Stock Is Soaring Today
    Market Realist10 days ago

    Why Advaxis Stock Is Soaring Today

    Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22. On July 12, Advaxis stock closed at $1.22 and hit its 52-week low of $1.15. Advaxis hit its 52-week high of $7.45 on September 11, 2017. Today, the FDA lifted its clinical hold on Advaxis’s IND (Investigational New Drug) application for the initiation of its Phase 1/2 trial of a combination therapy of axalimogene filolisbac and AstraZeneca’s (AZN) Imfinzi (duravalumab).

  • What’s Nektar Therapeutics’ Guidance for Fiscal 2018?
    Market Realist19 days ago

    What’s Nektar Therapeutics’ Guidance for Fiscal 2018?

    For fiscal 2018, Nektar Therapeutics (NKTR) has recently raised its guidance to ~$1.1 billion, as the company will account for payments related to its Bristol Myers Squibb (BMY) collaboration in Q2 2018, which will end on June 30, 2018. The company will recognize the collaboration-related upfront payment of $1 billion in the quarter. On excluding these payments, Nektar Therapeutics maintained its full-year 2018 outlook range of $100 million to $110 million.

  • Nektar’s Immuno-Oncology Clinical Trial Collaboration with Syndax
    Market Realist20 days ago

    Nektar’s Immuno-Oncology Clinical Trial Collaboration with Syndax

    Nektar Therapeutics (NKTR) and Syndax Pharmaceuticals (SNDX) have entered a collaboration for the evaluation of the efficacy and safety of the combination therapy of Nektar’s CD122-biased agonist NKTR-214 and Syndax’s small molecule Class 1 specific HDAC inhibitor entinostat for the treatment of patients suffering from metastatic melanoma that have previously reported treatment progression with an anti-PD-1 (programmed death receptor-1) agent. The recently presented preclinical study results showed that the NKTR-214+entinostat combination therapy significantly inhibited tumor growth in kidney and colon cancers. The trial will focus on establishing the recommended dosage of the combination therapy in the Phase 1b stage.

  • Wall Street Is Still Positive on Nektar’s Immuno-Oncology Drug
    Market Realist20 days ago

    Wall Street Is Still Positive on Nektar’s Immuno-Oncology Drug

    Does Nektar's Stock Price Correction Signal a Good Opportunity? Nektar Therapeutics reported its biggest fall of ~42% on June 4 after the company reported preliminary results for its phase one and phase two trials for the company’s IO (immuno-oncology) candidate, NKTR-214, which was being evaluated in combination with Bristol Myers Squibb’s (BMY) Opdivo for the treatment of patients suffering from stage-IV metastatic melanoma, renal cell carcinoma, and urothelial cancers. BMY stock fell ~3% on the day.

  • Nektar Therapeutics’ NKTR-181 Is Expected to Be Key Growth Driver
    Market Realist20 days ago

    Nektar Therapeutics’ NKTR-181 Is Expected to Be Key Growth Driver

    On June 14, 2018, Nektar Therapeutics announced new study data for its opioid therapy drug NKTR-181 at the 80th Annual Scientific Meeting of the CPPD (College on Problems of Drug Dependence) in San Diego, California. Nektar Therapeutics’ NKTR-181 is a NME (new molecular entity) and the first analgesic opioid molecule to exhibit a reduced incidence of specific CNS-mediated side effects such as euphoria through the targeted alteration of brain-entry kinetics. According to Steve Doberstein, the senior vice president and chief research and development officer of Nektar, “We are privileged that these meaningful new data from our clinical trials, as well as our translational research, were recognized for oral presentation at the prestigious CPDD meeting.

  • A Look at Nektar’s Recent Collaboration with Isoplexis
    Market Realist21 days ago

    A Look at Nektar’s Recent Collaboration with Isoplexis

    On June 26, Isoplexis, a privately held life sciences company, and Nektar Therapeutics, announced a collaboration focused on the functional impact of Nektar’s NKTR-214 in the clinical setting at the single-cell level with the aim to reveal the mechanism and potential immune correlation with the outcome. The collaboration aims to employ Isoplexis’s IsoCode Chip’s single-cell functional profiling for profiling the effects of Nektar’s NKTR-214 drug in both monotherapy and combination treatments in a clinical setting. IsoPlexis’s chief executive officer, Sean Mackay, said, “We are excited to collaborate with Nektar Therapeutics and further demonstrate the broad impact of NKTR-214 and its ability to induce critical T cell responses in cancer immunotherapy.

  • What’s behind Nektar Therapeutics’ ~38% Fall in June?
    Market Realist21 days ago

    What’s behind Nektar Therapeutics’ ~38% Fall in June?

    On June 27, Nektar Therapeutics (NKTR) ended the trading day at a closing price of $46.25. On the day, NKTR stock was trading ~164% higher than the 52-week low of $17.51 it reported on August 21, whereas the stock was trading ~59% lower than the 52-week high of $111.36 it reported on March 12. Currently, NKTR stock is trading lower than its 50-day moving average of $67.63 and its 200-day moving average of $79.32.

  • Wall Street Is Bullish on Nektar Stock despite Stock Price Slump
    Market Realist21 days ago

    Wall Street Is Bullish on Nektar Stock despite Stock Price Slump

    Does Nektar's Stock Price Correction Signal a Good Opportunity? Nektar Therapeutics (NKTR) is a development-stage biotechnology company that has a drug pipeline focused on the treatment of cancer, autoimmune diseases, and chronic pain. The company has entered a number of key collaborations recently to advance its drug pipeline.

  • Nektar Therapeutics Closed Higher on June 14
    Market Realistlast month

    Nektar Therapeutics Closed Higher on June 14

    The S&P 500’s top gainers on June 14 were: Nektar Therapeutics (NKTR) gained 5.5%. Royal Caribbean Cruises (RCL) gained 5.1%. Comcast Corp A (CMCSA) gained 4.6%. Discovery Comm A (DISCA) gained 4.5%. Incyte (INCY) gained 4.4%. Nektar Therapeutics 

  • Barrons.comlast month

    Former Incyte CEO Buys Slumping Nektar Shares

    Roy A. Whitfield, Nektar Therapeutics (NKTR) director, and former chairman and chief executive of Incyte (INCY), bought $290,200 in Nektar shares last week, buying as the biotech's shares show weakness. ...

  • Barrons.comlast month

    Biotech, Nektar Therapeutics Can't Handle Mondays

    Nektar Therapeutics (NKTR) went on a rollercoaster ride last week, and is down again today, following a downgrade, along with much of the rest of biotech. First, it notched a painful 40% plunge last Monday, in reaction to a presentation detailing its experimental drug NKTR-214 at a meeting at the American Society of Clinical Oncology, which didn't live up to high expectations.  Then, it bounced back for two days of gains of 6.5% and 7.2% on Tuesday and Wednesday, respectively, before the optimism ran out and it fell more than 11% on Thursday.  All of that movement means that while the intensely volatile shares are up 185% in the past 12 months, they've fallen more than 12% year to date. Today, the shares are down again, after H.C. Wainwright threw in the towel and downgraded Nektar to Neutral with a $54 price target.

  • S&P 500’s Top Losses: Nektar Therapeutics and Lam Research
    Market Realistlast month

    S&P 500’s Top Losses: Nektar Therapeutics and Lam Research

    The S&P 500’s top losses on June 7 were: Nektar Therapeutics (NKTR) declined 11.7%. Seagate Technology (STX) declined 5.9%. Lam Research (LRCX) declined 5.4%. J.M. Smucker (SJM) declined 5.4%. Advanced Micro Devices (AMD) declined 5%. Nektar Therapeutics 

  • Why Nektar Therapeutics Stock Stumbled 11.8% Today
    Motley Foollast month

    Why Nektar Therapeutics Stock Stumbled 11.8% Today

    Shares have been on a roller-coaster ride since the company presented updated study results for its latest drug and outlined its goals at an investor conference on Wednesday.

  • Barrons.comlast month

    After the Bell: 21 Out of 30 Dow Stocks Can't Be Wrong, Can They?

    The Dow Jones industrial Average gained nearly 100 points even as everything else fell apart. The Nasdaq Composite, which had been rallied for four days, sank 0.7% to 7635.07, while the S&P 500 dipped 0.1% to 2770.37. "The Dow continued higher, but the NASDAQ Composite took a hit," writes Todd Market Forecast's Stephen Todd.

  • Nektar Therapeutics: S&P 500’s Top Gainer
    Market Realist2 months ago

    Nektar Therapeutics: S&P 500’s Top Gainer

    The S&P 500’s top gainers on June 6 were: Nektar Therapeutics (NKTR) gained 7.2%. Equifax (EFX) gained 6.1%. Dish Network (DISH) gained 5.8%. Devon Energy (DVN) gained 5.6%. Adv Micro Devices (AMD) gained 5.5%. Nektar Therapeutics 

  • What You Should Know about Nektar’s Cash Flows and Valuations
    Market Realist2 months ago

    What You Should Know about Nektar’s Cash Flows and Valuations

    Nektar Therapeutics (NKTR) used up $52.5 million on operating activities in Q1 2018 compared with $34.6 million in Q1 2017. Operating cash flow in Q1 2018 included $57.5 million of net operating cash use along with $5 million for interest payments on Nektar’s senior secured notes partially offset by the receipt of a milestone payment of $10 million from Baxalta. Nektar expects cash used in operating activities in fiscal 2018 to increase as compared with fiscal 2017 mainly as a result of higher research and development expenses.

  • Analyzing Nektar Therapeutics’ Operational Performance
    Market Realist2 months ago

    Analyzing Nektar Therapeutics’ Operational Performance

    Nektar Therapeutics’ (NKTR) cost of goods sold increased from $6.1 million in Q1 2017 to $6.6 million in Q1 2018. This increase was due to Nektar’s clinical development of NKTR-214, NKTR-181, and NKTR-262 and preclinical activities for NKTR-255. Nektar Therapeutics expects research and development expenses to increase significantly in fiscal 2018 as compared to fiscal 2017 mainly on account of the development of NKTR-214 under its collaboration agreement with Bristol-Myers Squibb.

  • Barrons.com2 months ago

    After the Bell: Dow Gains 346 Points and Didn't Need Tech to Do It

    The Dow Jones Industrial Average gained more than 300 points today. Today, it was the Dow's turn. The Dow got a huge lift from Boeing (BA), which rose 3.2% to $371.56, and added 78.91 points to the price-weighted benchmark.

  • Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today
    Motley Fool2 months ago

    Why Advanced Micro Devices, Nektar Therapeutics, and Manitowoc Jumped Today

    Find out which of these stocks picked up the most ground.

  • Here's Why Nektar Therapeutics Jumped as Much as 17% Today
    Motley Fool2 months ago

    Here's Why Nektar Therapeutics Jumped as Much as 17% Today

    The biopharma stock is bouncing after a wild week.

  • Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap
    Investor's Business Daily2 months ago

    Nektar Attempts Recovery After Knocking $6 Billion Off Its Market Cap

    Nektar Therapeutics popped for the second day running Wednesday as it tried to recover from a melanoma presentation with Bristol-Myers Squibb.

  • How Was Nektar Therapeutics’ Top-Line Performance?
    Market Realist2 months ago

    How Was Nektar Therapeutics’ Top-Line Performance?

    In the first quarter of 2018, Nektar Therapeutics (NKTR) generated total revenues of $38 million compared with $24.7 million in the first quarter 2017. Nektar’s licensing and collaboration revenues rose more than 100% from $6 million in Q1 2017 to $13.7 million in Q1 2018. This increase was primarily due to the recognition of a milestone payment of $10 million received by Nektar in March 2018 resulting from the marketing authorization of Adynovi in the European Union in January 2018.

  • What’s the Upside Potential of Nektar Therapeutics?
    Market Realist2 months ago

    What’s the Upside Potential of Nektar Therapeutics?

    Nektar Therapeutics (NKTR) is a San-Francisco-headquartered biopharmaceutical company with a focus on research. It is developing drug candidates that make use of Nektar’s advanced polymer conjugate technology platforms. Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating, while one analyst has given it a “hold” rating.

  • What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?
    Market Realist2 months ago

    What’s behind Nektar Therapeutics Stock’s Recent Price Tumble?

    After a stellar rise in the past 12 months, Nektar Therapeutics (NKTR) stock fell more than 40% on June 4, which wiped out close to $6 billion of the company’s market cap. This drop was after Bristol Myers Squibb (BMY) and Nektar reported preliminary results from the currently ongoing phase one and two study for NKTR-214 in combination with Opdivo for treating patients with stage four metastatic melanoma, renal cell carcinoma, and urothelial cancers. The price of Bristol-Myers Squibb stock also witnessed selling pressure and fell almost 3% on June 4.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes